


#4

Express Mail Label No. EL585230615US

Date of Deposit: October 10, 2001

PATENT
Attorney Docket No: 17810-705 (CTI-N5 DIV11CON)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ART UNIT:	Not Yet Assigned	EXAMINER:	Not Yet Assigned
APPLICANTS:	Weiss et al.		
SERIAL NO:	09/925,911		
FILING DATE:	August 9, 2001		
FOR :	IN VITRO AND IN VIVO PROLIFERATION AND USE OF MULTIPOTENT STEM CELLS AND THEIR PROGENY		

October 10, 2001
Boston, MassachusettsAssistant Commissioner for Patents
Washington, D.C. 20231**PRELIMINARY AMENDMENT**

Prior to examination of the above-identified application, please amend the application as set forth below and consider the following remarks.:

In the Specification:

Please insert the sequence listing, pages 1-4 at the end of the specification.

At page 1, please insert the following before the section entitled "Field of the Invention":

RELATED APPLICATIONS

This application is a continuation of U.S.S.N. 08/484,203, filed June 7, 1995, which is a continuation in part of U.S.S.N. 08/270,412, filed July 5, 1994, which is a continuation of U.S.S.N. 07/726,812, filed July 8, 1991; a continuation in part of U.S.S.N. 08/385,404, filed February 7, 1995, which is a continuation of U.S.S.N. 07/961,813, filed October 16, 1992, which is a continuation in part of U.S.S.N. 07/726,812, filed July 8, 1991; a continuation in part of USSN 08/359,945, filed December 20, 1994, which is a continuation of U.S.S.N. 08/221,655, filed April 1, 1994, which is a continuation of U.S.S.N. 07/967,622, filed October 28, 1992,

FOOTNOTES

Variable	Mean	SD	Minimum	Maximum
Age	34.5	10.2	21	55
Gender	50.0	50.0	0	100
Marital status	75.0	25.0	0	100
Education	12.5	2.5	8	16
Income	15.0	5.0	10	20
Occupation	10.0	10.0	0	100
Religion	50.0	50.0	0	100
Health status	75.0	25.0	0	100
Stress level	60.0	20.0	0	100
Life satisfaction	70.0	30.0	0	100
Work satisfaction	65.0	25.0	0	100
Family satisfaction	70.0	30.0	0	100
Community satisfaction	60.0	20.0	0	100
Overall satisfaction	65.0	25.0	0	100

Nucleic acids may be obtained from neural cell cultures produced by using growth factors to induce the proliferation of multipotent neural stem cells. The resultant progeny may be passaged repeatedly to produce a sufficient number of cells to obtain representative nucleic acid samples. Clonal cultures may be produced. Nucleic acids may be obtained from both cultured normal and dysfunctional neural cells and from neural cell cultures at various stages of development. This information allows for the identification of the sequence of gene expression during neural development and can be used to reveal the effects of biological agents on gene expression in neural cells. Additionally, nucleic acids derived from dysfunctional tissue can be

compared with that of normal tissue to identify genetic material which may be the cause of the dysfunction. This information could then be used in the design of therapies to treat the neurological disorder. A further use of the technology would be in the diagnosis of genetic disorders or for use in identifying neural cells at a particular stage in development.


REMARKS

This Preliminary Amendment is being filed in order to incorporate the following into the above-identified patent application: the Sequence Listing, the Related Applications section, the Abstract and corrections to the specification.

CONCLUSION

On the basis of the foregoing amendments, Applicants respectfully submit that the pending claims are in condition for allowance. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact either of the undersigned at the telephone number provided below.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529

Christina V. Karnakis, Reg. No. 45,899

Attorney(s) for Applicants

c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Fax: (617) 542-2241

